Insulet Co. (NASDAQ:PODD) – Research analysts at Oppenheimer lowered their Q4 2019 earnings per share estimates for shares of Insulet in a note issued to investors on Wednesday, November 6th. Oppenheimer analyst S. Lichtman now expects that the medical instruments supplier will earn $0.07 per share for the quarter, down from their previous estimate of $0.15. Oppenheimer also issued estimates for Insulet’s FY2020 earnings at $0.77 EPS.
PODD has been the topic of a number of other research reports. Stifel Nicolaus assumed coverage on Insulet in a research report on Tuesday, October 22nd. They set a “hold” rating and a $163.00 price objective on the stock. Cowen set a $165.00 price objective on Insulet and gave the stock a “buy” rating in a research report on Monday, October 21st. Piper Jaffray Companies reiterated an “overweight” rating and set a $170.00 price objective (up previously from $160.00) on shares of Insulet in a research report on Wednesday. JPMorgan Chase & Co. upgraded Insulet from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $120.00 to $155.00 in a research report on Tuesday, August 6th. Finally, Svb Leerink lifted their price objective on Insulet from $160.00 to $185.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Ten equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $151.71.
Insulet stock traded up $4.59 during trading on Friday, reaching $169.46. 1,241,182 shares of the company were exchanged, compared to its average volume of 751,627. Insulet has a 52-week low of $70.80 and a 52-week high of $171.96. The company has a market capitalization of $8.73 billion, a P/E ratio of 3,389.20 and a beta of 0.96. The company has a debt-to-equity ratio of 2.43, a current ratio of 4.72 and a quick ratio of 3.91. The stock’s 50 day simple moving average is $154.39 and its two-hundred day simple moving average is $130.33.
Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the Zacks’ consensus estimate of $0.03 by ($0.02). Insulet had a return on equity of 9.46% and a net margin of 2.38%. The company had revenue of $192.12 million for the quarter, compared to analysts’ expectations of $179.50 million. During the same quarter in the previous year, the business posted $0.03 EPS. The business’s quarterly revenue was up 27.2% compared to the same quarter last year.
Hedge funds have recently bought and sold shares of the business. Lisanti Capital Growth LLC grew its stake in shares of Insulet by 9.2% in the third quarter. Lisanti Capital Growth LLC now owns 15,700 shares of the medical instruments supplier’s stock valued at $2,589,000 after buying an additional 1,320 shares in the last quarter. BBVA USA Bancshares Inc. acquired a new stake in shares of Insulet in the third quarter valued at $849,000. Carillon Tower Advisers Inc. grew its stake in shares of Insulet by 97.3% in the third quarter. Carillon Tower Advisers Inc. now owns 524,087 shares of the medical instruments supplier’s stock valued at $86,438,000 after buying an additional 258,424 shares in the last quarter. Eagle Asset Management Inc. grew its stake in shares of Insulet by 86.3% in the third quarter. Eagle Asset Management Inc. now owns 709,266 shares of the medical instruments supplier’s stock valued at $116,979,000 after buying an additional 328,620 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new stake in shares of Insulet in the third quarter valued at $792,000.
In other Insulet news, CEO Shacey Petrovic sold 689 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $145.69, for a total transaction of $100,380.41. Following the completion of the sale, the chief executive officer now owns 94,510 shares of the company’s stock, valued at $13,769,161.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Michael P. Spears sold 4,153 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.12, for a total value of $606,836.36. Following the sale, the senior vice president now directly owns 22,626 shares of the company’s stock, valued at approximately $3,306,111.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,491 shares of company stock valued at $806,124. 3.50% of the stock is owned by insiders.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.
Featured Story: Trading Strategy
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.